Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05672420
Other study ID # UHCT22668
Secondary ID
Status Not yet recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date January 1, 2023
Est. completion date January 31, 2025

Study information

Verified date January 2023
Source Wuhan Union Hospital, China
Contact Qiubai Li, Professor
Phone (027) 85726387
Email qiubaili@hust.edu.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of the study is to explore the safety and efficacy of umbilical cord derived mesenchymal stem cells in treatment-induced myelosuppression in patients with hematologic malignancies.


Description:

Despite the improved prognosis of patients with hematologic malignancies, almost all patients will experience severe myelosuppression induced by anti-cancer treatment, leading to a series of complications such as infection due to neutropenia, bleeding due to thrombocytopenia and/or impaired major organ function such as cardiac function due to anemia, which are the main reasons for dose reduction, dose interrruptions of anti-cancer treatment, failure of hematopoietic stem cell transplantation, and also patients' treatment-related death. It is of significant clinical importance and an urgent need to promote early recovery of myelosuppression and reduce risks of related complications as well as medical burdens. Umbilical cord derived mesenchymal stem cells (UC-MSCs), as a kind of stem cells with multipotential, can widely act on the functional cell units of bone marrow microenvironment and promote the repairment and regeneration of key cells such as hematopoietic stem cells, mesenchymal stem cells and endothelial cells, thus making it an ideal means for effectively promoting recovery of myelosuppression. Patients with hematologic malignancies and treatment-induced myelosuppression will be invited to participate in the Phase Ib/II study, to receive UC-MSCs intravenous infusion and follow-up visits of up to 2 years after enrollment.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 181
Est. completion date January 31, 2025
Est. primary completion date December 31, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: 1. Aged between 18 and 75 years old; 2. Either type of primary hematologic malignancies listed below: 1. Acute myeloid leukemia (AML, AML subtype M3 excluded) or acute lymphoblastic leukemia (ALL) diagosed according to the 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia, either treatment naive participants who are going to receive first induction therapy, or participants who failed first induction therapy and are going to receive re-inducton therapy; 2. AML or ALL participants who achieved remission and are going to receive consolidation therapy; 3. Relapsed/refractory AML or ALL participants who are going to receive first re-induction therapy; 4. Phase II trial will also include: participants with primary hematological maligancies who are going to receive autologous hematopoietic stem cell transplantation (allo-HSCT) whereas are poor mobilizers (CD34+cell count in peripheral blood was below 11-19/µL before collection, or the amount of CD34+ cells transfused was below 2×10^6/kg in allo-HSCT), and the participants' peripheral superficial veins have smooth blood flow which can meet the demand for intravenous drip; 3. The participant or his/her legal guardian is adequately informed of the nature and risks of the study, voluntarily participates in the study with signed informed consent; 4. Male or female; 5. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 to 2 (by the day anti-cancer therapy is initiated) 6. Estimated survival of at least 3 months; 7. Adequate major organ function: 1. Respiratory function: indoor oxygen saturation of at least 95%; 2. Cardiac function: ejection fraction of left ventricular of at least 45%; 3. Hepatic function: alanine aminotransferase/aspartate aminotransferase of at most 2.5 times/upper limit of normal value and serum total bilirubin of at most 1.5 times/upper limit of normal value; 4. Renal function: Serum creatinine of at most 1.5 times/upper limit of normal value; 8. Participants who do not receive any type of anti-cancer therapy within 2 weeks before enrollment (radiation therapy, chemotherapy and/or immune therapy, et al.), and treatment-associated toxicities induced by previous therapy has recovered to Grade 1 or below (except for low grade toxities such as alopecia). Exclusion Criteria: 1. Overt central nervous system manifestations of hematologic malignancies at diagnosis; 2. Secondary hematological maligancies; 3. Body mass index (BMI) of more than 30 kg/m^2; 4. Myelosuppression induced by conditions other than anti-cancer therapy; 5. Previous radiation therapy performed on sternum or pelvis; 6. Specifically diagnosed and uncontrolled infection at enrollment (Uncontrolled is defined as exhibiting ongoing signs and symptoms of infection without improvement despite anti-infective agents) ; 7. Uncontrolled active bleeding at enrollment; 8. Severe underlying comorbidities affecting survival, including cachexia, severe malnutrition, etc; 9. Estimated survival of at most 48 hours; 10. Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection; 11. History of or current human immunodeficiency virus (HIV) infection; 12. Continuous usage of immunosuppressants or received organ transplantation in the last 6 months; 13. Participation in clinical trials of other drugs within 6 weeks before enrollment; 14. Previous participation in clinical stem cell research; 15. Receiving any agent concurrently with UC-MSCs infusion which inhibits cell division (hydroxyurea, low-dose cytarabine or methotrexate, etc) ; 16. Severe allergic constitution, or known or suspected allergy to the study drug and its components; 17. Known contraindication to receiving hematopoietic growth factors, transfusion of blood components, anti-infective agents; 18. Female participants who are pregnant or breast feeding; 19. Participants with fertility plan; Note: For female participants, they should be surgical sterilized or post-menopausal, or agree to utilize a medically recognised method of contraception (such as intrauterine device, condom) during treatment period of the study and within 6 months after the end of treatment period of the study; For male participants, they should be surgical sterilized or agree to utilize a medically recognised method of contraception (such as intrauterine device, condom) during treatment period of the study and within 6 months after the end of treatment period of the study; 20. Participants suffering from mental illness; 21. Presence of drug abuse/addiction; 22. History of other malignancies other than hematological malignancies within 3 years; 23. Participants without signed informed consent; 24. Participants with poor compliance and are unable to complete the whole course of the study; 25. Participants with circumstances that, in the opinion of the investigator, may increase the risk of the participants or interfere with conduct of the clinical trial and the judgment of results (excessive tension, sensitivity or cognitive impairment, etc) ; 26. Participants with other circumstances that are ineligible for enrollment in this study, in the opinion of the investigator.

Study Design


Intervention

Biological:
umbilical cord derived mesenchymal stem cells
umbilical cord derived mesenchymal stem cells, intravenous infusion

Locations

Country Name City State
China Wuhan Central Hospital Wuhan Hubei
China Wuhan Tongji Hospital Wuhan Hubei
China Wuhan Union Hospital Wuhan Hubei

Sponsors (3)

Lead Sponsor Collaborator
Wuhan Union Hospital, China Wuhan Central Hospital, Wuhan TongJi Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Dose-limiting toxicities(DLT) During the DLT observation period, the subject has an adverse event that is reasonably related to UC-MSCs infusion (possibly, likely or definitely related). 4 days after the last UC-MSCs dose, up to 12 days
Primary Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs) To investigate the safety characteristics, percentages will be calculated and grade will be evaluated. From the day that the last UC-MSCs dose is used to up to 21 days
Primary Maximum tolerated dose (MTD) During the dose-escalation phase, the highest dose of dose-limiting toxicity for subjects less than or equal to 1/3 in the dose group of at least 6 evaluble subjects of the study drug after the last UC-MSCs dose. From the day that the last UC-MSCs dose is used to up to 4 days
Secondary Time to absolute neutrophil count recovery To investigate the efficacy characteristics, time will be measured in days. From the start of anti-cancer therapy or completion of hematopoietic stem cell transplantation to up to 42 days
Secondary Incidence of febrile neutropenia To investigate the efficacy characteristics, percentages will be calculated. From the start of anti-cancer therapy or completion of hematopoietic stem cell transplantation to up to 42 days
Secondary Duration of febrile neutropenia To investigate the efficacy characteristics, the duration will be measured in days. From the start of anti-cancer therapy or completion of hematopoietic stem cell transplantation to up to 42 days
Secondary Incidence of severe thrombocytopenia To investigate the efficacy characteristics, percentages will be calculated. From the start of anti-cancer therapy or completion of hematopoietic stem cell transplantation to up to 42 days
Secondary Time to severe thrombocytopenia recovery To investigate the efficacy characteristics, time will be measured in days. From the start of anti-cancer therapy or completion of hematopoietic stem cell transplantation to up to 42 days
Secondary Incidence of severe anemia To investigate the efficacy characteristics, percentages will be calculated. From the start of anti-cancer therapy or completion of hematopoietic stem cell transplantation to up to 42 days
Secondary Time to severe anemia recovery To investigate the efficacy characteristics, time will be measured in days. From the start of anti-cancer therapy or completion of hematopoietic stem cell transplantation to up to 42 days
Secondary Incidence of infetion To investigate the efficacy characteristics, percentages will be calculated. From the start of anti-cancer therapy or completion of hematopoietic stem cell transplantation to up to 42 days
Secondary Duration of infetion To investigate the efficacy characteristics, the duration will be measured in days. From the start of anti-cancer therapy or completion of hematopoietic stem cell transplantation to up to 42 days
Secondary Incidence of bleeding To investigate the efficacy characteristics, percentages will be calculated. From the start of anti-cancer therapy or completion of hematopoietic stem cell transplantation to up to 42 days
Secondary Duration of bleeding To investigate the efficacy characteristics, the duration will be measured in days. From the start of anti-cancer therapy or completion of hematopoietic stem cell transplantation to up to 42 days
Secondary Application rate of blood transfusion To investigate the efficacy characteristics, percentages will be calculated. From the start of anti-cancer therapy or completion of hematopoietic stem cell transplantation to up to 42 days
Secondary Application rate of anti-infective agents To investigate the efficacy characteristics, percentages will be calculated. From the start of anti-cancer therapy or completion of hematopoietic stem cell transplantation to up to 42 days
Secondary Time to achievement of complete remission To investigate the efficacy characteristics, time will be measured in days. From enrollment to up to 28 days
Secondary Duration of complete remission To investigate the safety characteristics, the duration will be measured in days or months. From enrollment to maximun up to 2 years
Secondary Event free survival From enrollment to the day of any event. From enrollment to maximun up to 2 years
Secondary Overall survival From enrollment to the day of death caused by any reason. From enrollment to maximun up to 2 years
Secondary Incidence of infusion reactions in 2 years To investigate the safety characteristics, percentages will be calculated. 2 years since the last UC-MSCs infusion
Secondary Incidence of secondary tumor in 2 years To investigate the safety characteristics, percentages will be calculated. 2 years since the last UC-MSCs infusion
Secondary Cumulative incidence of relapse of primary disease in 2 years To investigate the safety characteristics, percentages will be calculated. 2 years since the last UC-MSCs infusion
See also
  Status Clinical Trial Phase
Terminated NCT00801931 - Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders Phase 1/Phase 2
Completed NCT02948283 - Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia Phase 1
Completed NCT03341338 - Genes-in-Action - Hepcidin Regulation of Iron Supplementation
Completed NCT00060398 - Epoetin Alfa With or Without Dexamethasone in Treating Fatigue and Anemia in Patients With Hormone-Refractory Prostate Cancer Phase 3
Recruiting NCT05384691 - Efficacy of Luspatercept in ESA-naive LR-MDS Patients With or Without Ring Sideroblasts Who do Not Require Transfusions Phase 2
Not yet recruiting NCT06309641 - Methemoglobinemia Following Intravenous Iron Treatment
Completed NCT02930850 - Spot-Check Noninvasive Hemoglobin (SpHb) Clinical Validation N/A
Completed NCT02912533 - A Long-term Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD) Phase 3
Completed NCT02888171 - Impact of Ferric Citrate vs Ferrous Sulfate on Iron Parameters and Hemoglobin in Individuals With CKD and Iron Deficiency N/A
Completed NCT03822884 - Pharmacokinetic/Pharmacodynamic Study of 3 Subcutaneous Single Dose Epoetin Alfa Formulations in Healthy Volunteers Phase 1
Completed NCT02912494 - A Phase III Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD) Phase 3
Completed NCT02603250 - Evaluation of Hemoglobin Measurement Tools for Child Anemia Screening in Rwanda N/A
Completed NCT02384122 - Efficacy of Octreotide on Blood and Iron Requirements in Patients With Anemia Due to Angiodysplasias Phase 3
Completed NCT02176759 - Iron Absorption From Rice Fortified With Ferric Pyrophosphate N/A
Completed NCT01922479 - Pilot Study of Ferric Carboxymaltose to Treat Iron Deficiency in Asians With Heart Failure Phase 4
Withdrawn NCT01934842 - A Study to Compare Analyte Levels in Blood Collected Using an Investigational Collection Device With a Commercial Predicate N/A
Completed NCT02310113 - Transfusion and Skeletal Muscle Tissue Oxygenation N/A
Completed NCT01693029 - Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa Phase 3
Completed NCT01458028 - Age and Gender Effects on the Pharmacokinetics of BAY85-3934 Phase 1
Terminated NCT01535781 - Study of the Effect of Tranexamic Acid Administered to Patients With Hip Fractures. Can Blood Loss be Reduced? N/A